

CD27

Research Grade Varlilumab

Catalog No.	DHD72201A DHD72201B	Quantity:	100 µg 1.0 mg
Alternate Names:	1F5, CDX-1127, CAS: 1393344-72-3		
Description:	Varlilumab is a fully human monoclonal antibody (mAb) that targets CD27, a critical molecule in the activation pathway of lymphocytes. Like CD40, CD27 can be effectively manipulated with activating antibodies to induce potent anti-tumor responses, and may result in less toxicities due to its restricted expression and regulation. Varlilumab is a novel, first-in-class, agonist CD27 antibody that stimulates the CD27 pathway, which results in T-cell activation and antitumor activity in tumor models. This first-in-human, dose-escalation and expansion study evaluated the safety, pharmacology, and activity of varlilumab in patients with advanced solid tumors.		
UniProt ID (target):	P26842		
Specificity:	Human CD27 antigen		
Source:	XtenCHO cell line		
Isotype:	Human IgG1-kappa		
INN:	Varlilumab		
Concentration:	1.0 mg/ml, lot specific		
Formulation:	0.01M PBS, pH 7.4		
Purity:	> 95% as determined by SDS-PAGE		
Purification:	Protein A/G affinity chromatography		
Endotoxin:	≤ 0.01 EU/µg by LAL analysis		
Storage & Stability:	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

